Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Y1S1- Fundamentals of Medicine > Clinical Pharmacology and Therapeutics > Flashcards

Clinical Pharmacology and Therapeutics Flashcards

1
Q

how much do prescriptions cost the NHS a year?

A

around 15 billion/year or 10% of all healthcare needs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

lifestyle drugs

A

to feel better- not for treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Antibiotics for

A

infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Analgesics for

A

pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Chemotherapy for

A

malignancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Statins for

A

hypercholesterolaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

ACE inhibitors for

A

heart disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Proton pump inhibitors for

A

dyspepsia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

pharmacodynamics

A

what a drug does to the body

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

pharmacokinetics

A

what the body does to a drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what are receptors made of?

A

glycoproteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

channel linked receptors

A

ligand binding opens and closes them

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

kinase linked receptors

A

Linked directly to an intracellular protein kinase that triggers a cascade of phosphorylation reactions (eg. insulin receptor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

DNA linked receptors

A

• Binding of a ligand promotes or inhibits synthesis of new proteins which may take time to promote a biological effect (eg. steroid receptors)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

agonist

A

mostly reversible
• ligand that binds to a receptor protein to produce a conformation change which is signals for the initiation of a biological response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

as free ligand concentration increases,

A

so does the proportion of receptors occupied, hence biological effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

partial agonist

A

• activated signalling pathway to lesser extent than maximum potential of receptors available (less of an effect than a full agonist)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

inverse agonist

A
  • ligand that produces the opposite effect to the full agonist when they bind to a receptor
  • Useful on receptors that when not acted upon by a drug would be constitutively active
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

competitive antagonist

A

occupies a receptor that would otherwise eb occupied by an endogenous molecule and prevents it from binding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

noncompetitive antagonist

A

binds to allosteric site and brings about conformation change that stops receptor from working

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

irreversible antagonist

A
  • Non-competitive antagonist whose effect persists even after antagonist has been removed
  • Antagonism only disappears when new proteins or enzymes are synthesised
  • Ex. Aspirin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

partial antagonist

A

able to activate a receptor after it binds to it but is unable to produce a maximal signalling effect even when all receptors are occupied, when mixed with full antagonists, they can reduce biological response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

receptor affinity

A

how strong the attachment between drug and receptor is and how long it will take to dissociate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

drugs with high affinity

A

low concentrations as they bind well and for a long time, produce effects when concentration falls

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

what does the log10 dose response curve look like?

A

sigmoidal dose-response curve (kinda looks like an S)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Emax

A

point where S flattens at the top, dose no longer increases effect of drug, receptors are full

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

ED50

A

dose that produces a response that is half of Emax

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

ED

A

effective dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

efficacy

A

extent to which a drug can produce a response when all available receptors or binding sites are occupied

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

potency

A

amount of drug required for a given response (combined with efficacy), relates to affinity for receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

how can differences in potency be overcome?

A

giving the less potent drug in high doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

therapeutic efficacy

A

compares two drugs that bind to difference receptors and have different mechanisms but provide same therapeutic effect to see which one has the greater effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

specificity

A

drug that is specific to one receptor only acts on that receptor, no matter what the dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

agonist selectivity

A

If it has a higher ED50 for one receptor we can see it is more selective for it so to have the same effects at other receptors, it would need a higher dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

antagonist selectivity

A

competitive antagonist increase the dose required to reach the Emax- moves the curve to the right
if the competitive antagonist pushes the curve right for one receptor move than another, it is more selective for that receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

therapeutic index

A

ratio between the dose of a drug that causes adverse effects and the dose that achieves therapeutic effects
• Drugs with higher therapeutic index are preferred

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

factors that affect pharmacokinetics

A

age (renal function), sex, body weight, impaired organ function, genetic variation, environmental factors, food, drug interactions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

larger body weight effect on drugs

A

drugs are more diluted in blood stream so drug dose must be scaled depending on patient body weight

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

older age effect on drugs

A

need lower doses of drugs and experience prolonged effects, aging is also associated with changes in drug metabolism and excretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

impaired liver function leads to

A

reduced drug metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

impaired renal function leads to

A

reduced excretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

example of genetic variation effect on drugs

A

prolonged paralysis of those with low or atypical plasma cholinesterase following administration of Suxamethonium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

4 stages of pharmacokinetics

A
  • Absorption
  • Distribution
  • Metabolism
  • Excretion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

enteral routes of absorption

A

oral, buccal, sublingual, rectal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

parenteral routes of absorption

A
  • intramuscular- simple to administer, unpredictable rate of absorption, painful e. vaccinations
  • intravenous (IV)
  • subcutaneous- drugs need to be absorbed well by fat and repeated injections can hinder absorption, invasive
  • inhaled- must be inhaled into the target airways in the lung
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

topical application of drug

A

delivered directly to the place its needed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

oral route of absorption

A
  • convenient + simple
  • can be self-administered
  • ideal for long term treatments for less acute illnesses
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

IV route of absorption

A
  • No concerns about absorption
  • Rapidly achieves high drug absorptions
  • No ‘first pass’ effect
  • Ideal for v ill patients where rapid, certain outcome is critical to outcome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

drug distribution

A

movement of drug into and out of the blood to other tissues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Key factors involved in drug distribution:

A

protein binding, water/lipid solubility (ionisation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

where are hydrophilic water-soluble drugs more likely to be?

A

plasma as blood is highly hydrophilic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

where are hydrophobic fatty drugs likely to be?

A

fatty compartment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

why dose a drug need to have a degree of lipid solubility?

A

to diffuse across cell membrane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

drug distribution passive or active?

A

Majority of drug distribution is passive, some may be active

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

volume of distribution

A

apparent volume of that dose appears to have distributed into shortly after intravenous injection based on plasma drug concentration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

what can increase volume of distribution

A

Renal failure and liver failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

what can decrease volume of distribution

A

dehydration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

site of drug metabolism

A

liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

importance of water solubility

A

excretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

drug interactions- inducing metabolism enzymes in liver, effect of this and what drugs can do this?

A

results in faster elimination of a dug, shorter half-life, reduced activity, increase patient’s exposure to toxic metabolites
- Drugs that can do this= phenytoin (anti-seizure), rifampicin (antibiotic) and chronic alcohol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

drug interactions-inhibiting metabolism enzymes in liver, effect of this and what drugs can do this?

A

result in slower elimination, longer half-life, increased activity, potential drug accumulation and toxic effects so standard dose of second drug will give higher plasma concentration
- Drugs that can do this: ciprofloxacin, erythromycin, cimetidine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

what drugs should drug interactions be considered for?

A

warfarin, oral contraceptives and morphine which require a stable plasma concentration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Phase 1 metabolism: oxidation

A
  • Oxidation in microsomal mixed function oxidase system
  • Once a drug goes through this, it is usually pharmacologically inactive
  • Some drugs can be excreted after this but most require phase II
  • Site of drug interactions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

phase 2 metabolism: conjugation

A
  • Conjugation of phase I metabolite with another molecule to increase water solubility
  • Examples: acetylation or glucuronidation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

first pass metabolism

A
  • Major determinant of peak plasma drug concentration for oral drugs
    Drug molecules absorbed from the stomach or any part of the small intestine must pass through the portal venous system and the liver sinusoids
  • Can be metabolised by enzymes in intestinal wall and liver before entering system circulation.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

3 effects of first pass metabolism

A
  • Biotransformation of active drug to inactive metabolite  reduce drug response
  • Active drug can be changed into an active metabolite  no effect on drug response
  • Inactive drug (pro-drug) changed into active metabolite  increasing drug response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

Drugs that are known to be affected by first pass metabolism:

A

aspirin, oestrogen, amitriptyline, glyceryl trinitrate

68
Q

routes of drug excretion

A
  • Renal excretion
  • Biliary excretion
  • Faeces
  • Breast milk
  • sweat
69
Q

for what drugs is urinary excretion the usual route?

A

low molecular weight drugs that are sufficiently water soluble to avoid reabsorption from the tubule

70
Q

what happens to lipid soluble drugs that have been filtered in?

A

diffuse back into body down a concentration gradient as urine becomes more concentrated during passage through renal tubule

71
Q

what can urine pH affect?

A

pH partitioning of drugs between plasma and urine- acids have tendency to accumulate in basic compartments (& vice versa) so urine’s low pH may affect where drugs accumulate

72
Q

for what drugs is fecal excretion the usual route?

A

large molecular weight drugs and ones that undergo conjugation with glucuronide

73
Q

where do molecules of drugs that enter bile after liver metabolism go?

A

carried into the intestinal lumen and are excreted in the faeces

74
Q

entero-hepatic circulation

A

recycling between the liver, bile, gut and portal vein

75
Q

effect of entero-hepatic circulation on active drugs

A

prolongs residence time of drugs in body and effect

76
Q

effect of broad spectrum antibiotics and other drugs killing bacterial flora

A

allows recycling of glucuronide conjugates  reduce reabsorption and drug availability

77
Q

drug clearance

A
  • volume of plasma which is completely cleared of drug per unit time
  • cause by either liver metabolism or renal excretion
  • drugs with high rate of clearance= short half life
78
Q

bioavailability

A
  • fraction of administered dose of unchanged drug that reaches system circulation
  • all of an intravenous dose enters systemic circulation but not true for other routes
79
Q

what does oral bioavailability depend on?

A
  • Gastric acid destruction (insulin can’t be given orally)
  • Formulation of drug (slow release or enteric coated)
  • First pass of metabolism (morphine, glyceryl trinate)
  • Solubility, ionisation, food, diarrhoea etc
80
Q

first order kinetics

A

constant fraction of drug is clear in unit time, exponential decrease in drug, most drugs clear like this

81
Q

zero order kinetics

A

constant amount of drug is cleared in unit time, metabolism has limited capacity- becomes saturated, elimination rate has reached a maximum, if drug is administered at a rate faster than its clearance then it will progressively accumulate eg. ethanol, phenytoin

82
Q

half life

A
  • Time taken for plasma concentration of drug to halve
  • Concept that only related to first order metabolism
  • Half-life remains constant throughout period of drug elimination
83
Q

steady state

A

point where elimination rate and absorption rate are equal

84
Q

what happens if repeated doses aren’t given when previous doses haven’t been eliminated?

A

drug will progressively accumulate

85
Q

long half life

A 
•	Slow to reach steady state
•	Loading dose may be needed
•	Slow to be eliminated
•	Less regular dosing
Eg. atenolol 8h
86
Q

short half life

A 
•	Rapid steady state
•	Fine control
•	Not suitable orally
•	More regular dosing required
Eg. dobutamine 2mins
87
Q

loading dose

A
  • In order to reach a target steady state plasma concentration with long half life drugs before 5 half lives, you can give an initial dose (loading dose) that is much larger than maintenance dose and equivalent to amount of drug required in body at steady state
  • Peak plasma concentration that is close to steady state concentration can be maintained by maintenance doses
88
Q

optimal dose interval

A

trade-off between convenience and constant level of drug exposure

89
Q

modified release formulations

A

tablets that break up slowly so is released progressively over several hours, allow drugs with short half lives to be given less often while having a smooth onset and decline in effect

90
Q

drug toxicity

A

adverse effect that occurs because dose or plasma concentration has risen above therapeutic range, can be unintentional or intentional drug overdose

91
Q

type A (augmented) ADR

A 
•	dose related
•	common 
•	usually detected in drug development
•	usually mild	
eg. Warfarin can cause subcutaneous haemorrhage
92
Q

type B ADR

A

• non predictable
• rare and severe
• usually remain undiscovered until post licensing
eg. Practlol (beta blocker) causes sclerosing peritonitis (fibrous thickening of the peritoneum in the abdomen)

93
Q

2 genetic factors that commonly have an effect on ADRs?

A
  • cytochrome P450 enzyme- vital for drug metabolism so polymorphisms are associated with different ADRs
  • HLA (human leukocyte antigen)- important for immunity
94
Q

drugs that may affect cell division or protein/DNA synthesis- teratogenesis

A

Thalidomide, warfarin, phenytoin, steroids, alcohol

95
Q

drugs that cause altered growth

A

Smoking, tetracycline

96
Q

drugs that interfere with labour

A

Beta blockers affect uterine muscles

97
Q

Respiratory or cardiovascular depressant that can cross the placenta

A

Opioids

98
Q

drugs that often cause ADRs

A

aspirin, diuretics, warfarin, NSAIDs and opioid analgesics

99
Q

common ADR

A

GI bleeding

100
Q

what do ADR cost the NHS and it’s prevalence?

A

£466 million and prevalence is 6.5% of admissions

101
Q

hypersensitivity drug reactions (allergic)

A
  • Type B reactions: not dose related, potentially v serious
  • Common targets of allergic drug reactions: skin (rashes), lungs (airway constriction), haematopoiesis
  • Penicillin is an example of a Type I reaction (anaphylaxis)
102
Q

what is the autonomic nervous system divided into?

A

sympathetic and parasympathetic system

103
Q

sympathetic system effect on heart

A

• Increases heart rate, conduction rate, contractility (force of contraction), stroke volume and cardiac output allows more blood to be pumped

104
Q

sympathetic system effect on lungs

A

bronchodilation by relaxing smooth muscle surrounding bronchi and bronchioles  less resistance to airflow and improved transfer of oxygen and carbon dioxide (adequate oxygen supply to muscles that need it)

105
Q

sympathetic system effect on kidney

A

constriction of renal arterioles (reduction of blood flow into kidney and urine production), releases renin from juxtaglomerular apparatus to cause vasoconstriction main target is to increase blood pressure

106
Q

sympathetic system effect on GI tract

A

reduction of digestion so there is more blood available for muscles by decreasing peristalsis, constriction of smooth muscles in sphincters ot reduce movement of food

107
Q

sympathetic system effect on liver

A

breaks down adipose tissue to release free fatty acids that act as energy stores, promotes glycogenolysis and gluconeogenesis (both produce glucose

108
Q

sympathetic system effect on bladder

A

relaxes smooth muscle of the bladder wall  reduced possibility of voiding

109
Q

sympathetic system effect on men’s genitals

A

constricts prostate smooth muscle making it more difficult to urinate

110
Q

sympathetic system effect on muscles and eyes

A
  • Increases circulation to muscles
  • Releases energy stores
  • Dilates pupils
111
Q

what are catchecholamines synthesised from?

A

the amino acid phenylalanine

112
Q

site of synthesis and storage of noradrenaline

A

Terminal branches of the sympathetic postganglionic fibres have swellings that form synaptic contact with the effector organ

113
Q

release of noradrenaline stimulated by

A

Arrival of nerve impulses cause noradrenaline to be released from granules in the presynaptic terminal into the synaptic cleft

114
Q

action of noradrenaline is terminated by

A
  • Diffusion from the site of action
  • Reuptake back into the presynaptic nerve ending where it is inactivated by the enzyme monoamine oxidase (MAO) in mitochondria
  • Metabolism locally by the enzyme catechol-O-methyl-transferase (COMT)
115
Q

4 types of adrenoreceptors (postsynaptic cell surface receptors for catecholamines )

A
  • alpha1-adrenoreceptor causing vasoconstriction of blood vessels
  • alpha2-adrenoreceptor (in presynaptic membranes where noradrenaline release form presynaptic terminals inhibits it’s own release by feedback inhibition
  • beta1-adrenoreceptors (mainly in heart) increases force and rate of contraction
  • beta2-adrenoreceptors (lung) bronchial smooth muscle relaxation in bronchi and (blood vessels) vasodilation
116
Q

alpha 1 agonists

A

noradrenaline, adrenaline, phenylephrine, ephedrine

for treatment of: Cardiovascular collapse & Nasal congestion

117
Q

alpha 2 agonist

A

clonidine

for the treatment of: hypertension

118
Q

adverse effects of alpha 1 agonists

A

hypertension, tachycardia, angina

119
Q

alpha 1 antagonist

A

prazosin, doxazosin, tamsulosin
Indicated for the treatment of:
- Hypertension, benign prostatic hypertrophy

120
Q

adverse effects of alpha 1 antagonists

A

Adverse effects: hypertension, dizziness, nasal congestion

121
Q

nonselective beta 1 and beta 2 agonist

A

adrenaline (emergency situations), isoprenaline

treatment of: anaphylaxis, cardiac arrest

122
Q

heart beta 1 receptors

A

dobutamine

treatment of: severe heart failure

123
Q

non selective beta 1 and beta 2 antagonists

A

propanolol

treatment of: tremor

124
Q

cardoselctive beta 1 antagonist

A

atenolol

treatment of: hypertension, angina pectoris, heart failure

125
Q

adverse effects of beta 1 and 2 antagonists

A
  • B1: brachycardia, heart failure

- B2: bronchospasm, cold peripheries, lethargy

126
Q

why can adrenoreceptor drugs have effects at other receptor subtypes at high enough concentration?

A

not totally selective

127
Q

alpha1 receptor stimulated

A

phospholipase C is activated and there is an increase in IP3 and DAG

128
Q

alpha2 receptor stimulated

A

decreased activity of adenyl cyclase + lower concentrations of cAMP and Ca2+

129
Q

beta1 receptor stimulated

A

increased activity of adenyl cyclase + higher concentrations of cAMP and Ca2+

130
Q

beta2 receptor stimulated

A

increased activity of adenyl cyclase + lower concentrations of cAMP and K+

131
Q

effect of parasympathetic system on heart

A

decreased rate + force of contraction + conduction velocity

132
Q

effect of parasympathetic system on lungs

A

bronchial muscle contraction, increased gland secretions (mucus)

133
Q

effect of parasympathetic system on GI tract

A

increased motility, relaxation of sphincters, glycogen synthesis is stimulated

134
Q

effect of parasympathetic system on pupil and arteries

A
  • Constricts pupil
  • Increasing lacrimal gland secretions (production of tears)
  • Dilation of arteries
135
Q

effect of parasympathetic system on bladder

A
  • Relaxation of bladder sphincter
136
Q

why are quaternary ammonium compounds less likely to cross lipid barriers

A

more soluble in water

137
Q

why can small tertiary amines cross lipid barriers?

A

low molecular weight

138
Q

why can large tertiary amines cross lipid barriers?

A

lipophilicity

139
Q

muscarine

A

direct acting acetylcholine receptor agonist, binds to the same protein receptors and activates them in the same way that acetylcholine does.

140
Q

where are muscarinic Ach receptors located?

A

parasympathetic nervous system and the CNS

141
Q

5 subtypes of muscarinic receptors

A
  • M1 receptors- neural (slow EPSP- excitatory postsynaptic potentials- in ganglia)
  • M2 receptors- cardiac, decrease in heart rate and force of contraction
  • M3 receptors- glandular secretion, contraction of visceral smooth muscle, vascular relaxation
  • M4- CNS
  • M5
142
Q

how are muscarinic acetylcholine receptors activated?

A

acetylcholine is released from postganglionic nerve endings where it activates muscarinic acetylcholine receptors on effect tissues

143
Q

functions of muscarinic receptors

A
  • Activate phospholipase C leading to production of IP3 (releasing Ca2+) and diacyl glycerol (DAG)- M1, M2, M3
  • Inhibit adenylate cyclase causing a decrease in the levels of cAMP- M2, M4
  • Open (activate) K+ channels, important for parasympathetic effect on heart- M2
  • Inhibit Ca2+ channels- M2
144
Q

Parasympathomimetic/ Cholinomimetic

A

drugs that mimic effects of parasympathetic nerve simulation, particularly by activation of responses mediated by muscarinic cholinergic receptors

145
Q

direct acting agonists on muscarinic receptors

A
  • Have mainly muscarine effects at end effectors
  • Similar structure to acetylcholine
  • Most synthetic direct acting compounds do not have CNS effects but plant alkaloids muscarine and pilocarpine can enter CNS
146
Q

choline esters- direct acting muscarinic agonists

A
  • Acetylcholine- too unstable in plasma to be an effective drug, has both muscarinic and nicotinic effects
  • Bethanechol- not hydrolysed by cholinesterase, very weak as nicotinic agonist, primarily a muscarinic agonist
147
Q

natural plant compounds- direct acting muscarinic agonists

A

neither are selective for types of muscarinic receptors, muscarine, pilocarpine

148
Q

indirect acting agonists on muscarinic receptors

A
  • Potentiate transmission at all cholinergic junctions therefore have muscarinic, ganglionic and skeletal muscle effects
  • Have CNS effects if permeable to blood-brain barrier
149
Q

reversible inhibitors of Ach-esterase that increase concentration of Ach that prolongs lifetime in the synapse

A
  • Physostigmine- tertiary plant alkoid

- Neostigmine- synthetic quaternary compound

150
Q

irreversible inhibitors of Ach-esterase that increase concentration of Ach that prolongs lifetime in the synapse

A

Organophosphates

a. Insecticide
b. Ecothiopate
c. Military nerve gases

151
Q

organophosphates

A

extremely lipophilic so they can cross are barriers including blood-brain

152
Q

main uses of muscarinic receptor agonists

A

glaucoma, intestinal & urinary atony and Alzheimer’s disease

153
Q

drugs used for treatment of Alzheimers

A

donepezil (mild cholinesterase), rivastigmine (delay in decline of cognitive functions due to AD)

154
Q

drugs used for treatment of atony

A

bethanechol (direct acting), neostigmine (indirect acting)
Act by increasing peristalsis in intestines and micturition in bladder (contraction of muscles) by acting on muscarinic receptors there

155
Q

drugs used for treatment of glaucoma

A

pilocarpine (direct acting) administered as eye drops, physostigmine, ecothiopate (indirect acting so both longer lasting)

156
Q

muscarinic antagonists

A
  • Usually competitive antagonists of muscarinic receptors

- Have little effect on ganglion and skeletal muscle nicotinic receptors

157
Q

examples of muscarinic antagonists

A

Atropine and hyoscine (tertiary amines)- atropine is the prototypical muscarinic antagonist and hyoscine is more lipophilic  absorbed through gut and can cross through CNS

158
Q

antimuscarinic for asthma

A

ipratropium

159
Q

therapeutic uses of atropine

A

asthma
preanesthetic medication
opthamological uses
poisoning by muscarinic agonists

160
Q

therapeutic use for benztropine

A

(atropine derivative)

Parkinson’s disease

161
Q

Ach release blockers

A

eg. botulinium toxin, acts as protease enzyme on proteins that assist the docking of vesicles containing the neurotransmitter to the pre-synaptic membrane (stops contraction), prevention of Ach release can cause muscle paralysis and death or used to relax muscle spasm

162
Q

nicotinic Ach blockers

A

non depolarising blockers competitively antagonise Ach receptors to prevent depolarisation in post synaptic membrane (sarcolemma), based on curare (natural compound) and are reversed by anticholinesterases, can be used as anaesthetic, depolarising blockers agonise the receptor and continue to bind to keep ion channel shut

163
Q

anticholinesterases

A

prevent enzymatic breakdown of Ach so prolong presence and effects in NMJ, used to diagnose myasthenia gravis, reverse anaesthesia and increase cholinergic activity, irreversible anticholinesterases are dangerous  paralysis & cholinergic crisis

164
Q

muscle relaxants

A

relieve spasticity by acting in CNS, PNS or both to clock signal for contraction (multiple sclerosis, cerebral palsy), dantrolene orevents calcium release from the SR to block contraction but lack of muscle use can worsen disability

165
Q

suxamethonium

A

hydrolysed by acetylcholinesterase slowly, actions can’t be reversed

166
Q

dantrolene

A

peripherally acting muscle relaxant, prevents muscle contraction, used for severe spasticity of voluntary muscle and malignant hyperthemia

167
Q

St John’s Wort

A

herbal remedy for depression, may cause serotonin syndrome when taken with other depression medication  overexcitability, reduces effects of warfarin and other drugs by inducing their metabolism

Y1S1- Fundamentals of Medicine (11 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions